Biotechnology company SeaBeLife has secured orphan drug designation (ODD) from the European Medicines Agency (EMA) for its drug candidate SBL01 in the treatment of acute liver failure (ALF).

ALF occurs when the liver suddenly loses its ability to function in a person without a pre-existing liver disorder, and carries a high morbidity and mortality rate (85% when transplantation is not feasible).

In the EU, the population of patients with ALF is estimated to be between 1.3 and 3.1 in 10,000, meeting the EMA’s orphan designation threshold.

With the designation, SeaBeLife will benefit from regulatory and financial incentives, including protocol assistance, reduced fees and market exclusivity for ten years upon approval.

According to the EMA’s Committee for Orphan Medicinal Products: “[SeaBeLife] has provided non-clinical data in a model of acute liver failure showing reduced hepatotoxicity and improved survival when SBL01 was used in combination with the currently authorised product in the applied for condition, as compared to the authorised product alone. The committee considered that this constitutes a clinically relevant advantage.”

SBL01 is a first-in-class small molecule ‘dual inhibitor of both necroptosis and ferroptosis’. Regulated cell death, such as necroptosis and ferroptosis, are key processes in acute liver failure where cells degenerate abruptly.

The molecule is capable of specifically inhibiting the induction cascade of these two cell death mechanisms and thereby enabling cellular protection and restoration of liver function.

“This is an important recognition of our strong preclinical research dataset. It reinforces our determination to push ahead with our approach in treating acute liver diseases and serious ophthalmologic disorders,” said Morgane Rousselot, CEO and co-founder of SeaBeLife. “This achievement comes at a time when we are actively preparing a Series A fundraising with venture capital funds, institutional funds and family offices.”

Diana Spencer, Senior Digital Content Editor, DDW